Alpha-toxin-elicited CX3CL1 release in Staphylococcus aureus pneumonia impairs bactericidal function of human monocytesCenter for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, Maryland, USA.
Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, Maryland, USA.
Center for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Respiratory, Inflammation and Autoimmunity, AstraZeneca, Gothenburg, Sweden.
Center for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Microbiology, Karolinska University Hospital, Huddinge, Sweden.
Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Institute of Intensive Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Division of Infection and Dermatology, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Center for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Center for Infectious Medicine, Department of Medicine, ANA Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Show others and affiliations
2025 (English)In: mBio, ISSN 2161-2129, E-ISSN 2150-7511, Vol. 16, no 11, article id e0268925
Article in journal (Refereed) Published
Abstract [en]
Staphylococcus aureus is an important human pathogen causing severe invasive infections. Pathogenesis is attributed to a wide array of virulence factors, including several potent exotoxins such as the pore-forming α-toxin. In this study, we found that patients with S. aureus respiratory tract infections had elevated CX3CL1 levels in airway fluid and plasma. Using human-organotypic lung models, we observed that stimulation of lung epithelium with α-toxin induces an intensified CX3CL1 expression apically in the epithelium as well as the release of CX3CL1. Blocking α-toxin or ADAM10 activity in organotypic lung using an α-toxin-blocking antibody or a specific ADAM10 inhibitor confirmed their role in modulating CX3CL1 cleavage and release. Analyses of CD14+ human monocytes in combination with a CX3CR1 inhibitor revealed that α-toxin-mediated CX3CL1 release induces CX3CL1-dependent chemotaxis. In line with these data, lung tissue from patients with S. aureus respiratory tract infection showed elevated CX3CL1 and CD14 staining as compared with tissue from patients with non-infectious lung diseases. Functional studies of monocytes showed that CX3CL1 released by lung models resulted in upregulated CD83 and downregulated CD86, as well as impaired killing of phagocytosed S. aureus. Furthermore, stimulation of monocytes with soluble CX3CL1 hampered their reactive-oxygen and nitric-oxide production. Taken together our data show that S. aureus triggers the release of lung epithelial CX3CL1, and we identify an immunomodulatory effect of α-toxin involving its cytotoxic and ADAM10-interacting properties, inducing CX3CL1 release leading to impaired monocyte effector function.IMPORTANCEExotoxins are essential virulence factors for the pathobiont S. aureus and contribute toward severe invasive infections such as pneumonia. S. aureus α-toxin is a pore-forming exotoxin that causes host cell lysis and severe lung pathology. We found that α-toxin drives the release of membrane-bound chemokine CX3CL1 by involving ADAM10-mediated proteolytic activity. Furthermore, the release of CX3CL1 modulated immune responses locally, as demonstrated by enhanced monocyte migration and reduced capacity of monocytes to kill ingested bacteria. CX3CL1-induced reduction in bacterial killing coincided with impaired production of reactive oxygen and nitric oxide species. This reveals a novel mechanism in the pathogenesis of S. aureus lung infections involving α-toxin-induced release of CX3CL1, leading to impaired bacterial killing by monocytes.
Place, publisher, year, edition, pages
American Society for Microbiology, 2025. Vol. 16, no 11, article id e0268925
Keywords [en]
ADAM10, CX3CL1, Staphylococcus aureus, chemotaxis, fractalkine, monocytes, pneumonia, α-toxin
National Category
Immunology in the Medical Area Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-124382DOI: 10.1128/mbio.02689-25ISI: 001592391400001PubMedID: 41081526Scopus ID: 2-s2.0-105025526851OAI: oai:DiVA.org:oru-124382DiVA, id: diva2:2006260
Funder
Karolinska InstituteStockholm County CouncilVinnovaNordForsk, 90456Swedish Research Council, 2018-151Swedish Research Council, 521-2014-6722Swedish Research Council, 2023-03056_3Swedish Childhood Cancer FoundationSwedish Society for Medical Research (SSMF)Swedish Research Council, 2014-396
Note
Our work was supported by grants from the Karolinska Institutet and Stockholm County council, as well as the Swedish Governmental Agency for Innovation Systems (VINNOVA) under the frame of NordForsk (Project no. 90456, PerAID), the Swedish Research Council under the frame of ERA PerMed (Project 2018-151, PerMIT), and by project grants from the Swedish Research Council (521-2014-6722, 2023-03056_3). P.C. received an MD-PhD scholarship from the Karolinska Institutet. M.L. was supported by the Swedish Children's Cancer Foundation. S.M.S. was supported by a grant from the Swedish Society for Medical Research (SSMF; P17-0179). S.M.S. and A.S.Z. were supported by the grant from Uniscientia Foundation grant. A.S.Z. was supported by the Swiss National Science Foundation (31003A_176252) and the Clinical Research Priority Program (CRPP) of the University of Zurich, Switzerland. A.W. was supported by a grant from the Swedish Research Council (2014-396).
2025-10-142025-10-142026-01-23Bibliographically approved